Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz International GmbH

Latest From Sandoz International GmbH

Sandoz Partner Samsung Bioepis Settles On Stelara In US

Samsung Bioepis has struck a US settlement with Johnson & Johnson that will allow partner Sandoz to launch the pair’s SB17 ustekinumab biosimilar to Stelara in early 2025, assuming FDA approval.

Biosimilars Deals

Sandoz Launches High-Concentration Adalimumab In Europe

Sandoz has launched the high-concentration version of its Hyrimoz adalimumab biosimilar rival to Humira in Europe.

Biosimilars Launches

Sandoz Mulls At-Risk Launch For US Natalizumab

As part of a wide-ranging discussion of its biosimilars business as it reported nine-month results, Sandoz has revealed that it is considering launching its Tysabri (natalizumab) biosimilar Tyruko “at risk” in the US, while also providing an update on its progress with adalimumab as well as certain key pipeline assets.

Biosimilars Strategy

Sandoz Sets Out Solid Growth In First Standalone Results

Reporting its first results as a standalone company, Sandoz has delivered double-digit growth in biosimilars for the first nine months of 2023, helping to lift the overall business as generics also enjoyed a more modest increase.

Sales & Earnings Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs